UVXY ETF & The VIX Spike higher – here is why and what to expect next

Bio­gen made a big M&A splash in Ju­ly with its $7.3 bil­lion buy­out of Rea­ta Phar­ma­ceu­ti­cals, which had just se­cured FDA ap­proval for a rare

Three ar­ti­cles de­tail­ing the mid-stage tri­al re­sults of Lykos Ther­a­peu­tics’ MD­MA-as­sist­ed ther­a­py were re­tract­ed by the med­ical jour­nal that pub­lished them, cit­ing a fail­ure by